ABSTRACT
Purpose
This prospective study evaluates our first clinical experiences with the novel ``BRachytherapy via artificial Intelligent GOMEA-Heuristic based Treatment planning'' (BRIGHT) applied to high-dose-rate prostate brachytherapy.
MethodS AND MATERIALs
Between March 2020 and October 2021, 14 prostate cancer patients were treated in our
center with a 15Gy HDR-brachytherapy boost. BRIGHT was used for bi-objective treatment
plan optimization and selection of the most desirable plans from a coverage-sparing
trade-off curve. Selected BRIGHT plans were imported into the commercial treatment
planning system Oncentra Brachy . In Oncentra Brachy a dose distribution comparison
was performed for clinical plan choice, followed by manual fine-tuning of the preferred
BRIGHT plan when deemed necessary.
The reasons for plan selection, clinical plan choice, and fine-tuning, as well as
process speed were monitored. For each patient, the dose-volume parameters of the
(fine-tuned) clinical plan were evaluated.
Results
In all patients, BRIGHT provided solutions satisfying all protocol values for coverage
and sparing. In four patients not all dose-volume criteria of the clinical plan were
satisfied after manual fine-tuning. Detailed information on tumour coverage, dose-distribution,
dwell time pattern, and insight provided by the patient-specific trade-off curve,
were used for clinical plan choice. Median time spent on treatment planning was 42
min, consisting of 16 min plan optimization and selection, and 26 min undesirable
process steps.
ConclusionS
BRIGHT is implemented in our clinic and provides automated prostate high-dose-rate
brachytherapy planning with trade-off based plan selection. Based on our experience,
additional optimization aims need to be implemented to further improve direct clinical
applicability of treatment plans and process efficiency.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer.Int J Radiat Oncol Biol Phys. 2013; 87: 270-274https://doi.org/10.1016/j.ijrobp.2013.05.022
- Prostate brachytherapy in men with gland volume of 100cc or greater: Technique, cancer control, and morbidity.Brachytherapy. 2013; 12: 217-221https://doi.org/10.1016/j.brachy.2012.10.002
- High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence.Int J Radiat Oncol Biol Phys. 2012; 82: 1376-1384https://doi.org/10.1016/j.ijrobp.2011.04.031
- IPIP: A new approach to inverse planning for HDR brachytherapy by directly optimizing dosimetric indices.Med Phys. 2011; 38: 4045-4051https://doi.org/10.1118/1.3598437
- Mixed integer programming improves comprehensibility and plan quality in inverse optimization of prostate HDR brachytherapy.Phys Med Biol. 2013; 58: 1041-1057https://doi.org/10.1088/0031-9155/58/4/1041
- Fast and fully-automated multi-criterial treatment planning for adaptive HDR brachytherapy for locally advanced cervical cancer.Radiother Oncol. 2020; 148: 143-150https://doi.org/10.1016/j.radonc.2020.04.017
- Novel tools for stepping source brachytherapy treatment planning: Enhanced geometrical optimization and interactive inverse planning.Med Phys. 2015; 42: 348-353https://doi.org/10.1118/1.4904020
- High-dose-rate prostate brachytherapy inverse planning on dose-volume criteria by simulated annealing.Phys Med Biol. 2016; 61: 1155-1170https://doi.org/10.1088/0031-9155/61/3/1155
- A fast multitarget inverse treatment planning strategy optimizing dosimetric measures for high-dose-rate (HDR) brachytherapy.Med Phys. 2017; 44: 4452-4462https://doi.org/10.1002/mp.12410
- Global convergence analysis of fast multiobjective gradient-based dose optimization algorithms for high-dose-rate brachytherapy.Phys Med Biol. 2003; 48: 599-617https://doi.org/10.1088/0031-9155/48/5/304
- Interactive multiobjective optimization for anatomy-based three-dimensional HDR brachytherapy.Phys Med Biol. 2010; 55: 4703-4719https://doi.org/10.1088/0031-9155/55/16/006
- A multi-criteria optimization approach for HDR prostate brachytherapy: II. Benchmark against clinical plans.Phys Med Biol. 2018; 63https://doi.org/10.1088/1361-6560/aae24f
- A GPU-based multi-criteria optimization algorithm for HDR brachytherapy.Phys Med Biol. 2019; 64https://doi.org/10.1088/1361-6560/ab1817
- Fast automated multi-criteria planning for HDR brachytherapy explored for prostate cancer.Phys Med Biol. 2019; 64https://doi.org/10.1088/1361-6560/ab44ff
- A hybrid evolutionary algorithm for multi-objective anatomy-based dose optimization in high-dose-rate brachytherapy.Phys Med Biol. 2003; 48: 399-415https://doi.org/10.1088/0031-9155/48/3/309
- Application of multiobjective genetic algorithms in anatomy based dose optimization in brachytherapy and its comparation with deterministic algorithms.Annu Rep Res React Institute, Kyoto Univ. 2001; 4: 3919-3922https://doi.org/10.1109/iembs.2001.1019698
- Multi-objective optimization.in: Burke E. Kendall G. Search methodologies. Springer, Boston, MA2014: 403-449
- Application and benchmarking of multi-objective evolutionary algorithms on high-dose-rate brachytherapy planning for prostate cancer treatment.Swarm Evol Comput. 2018; 40: 37-52https://doi.org/10.1016/j.swevo.2017.12.003
- Achieving highly scalable evolutionary real-valued optimization by exploiting partial evaluations.Evol Comput. 2020; 29: 129-155https://doi.org/10.1162/evco_a_00275
- Evaluation of bi-objective treatment planning for high-dose-rate prostate brachytherapy—A retrospective observer study.Brachytherapy. 2019; 18: 396-403https://doi.org/10.1016/j.brachy.2018.12.010
- GPU-accelerated bi-objective treatment planning for prostate high-dose-rate brachytherapy.Med Phys. 2019; 46: 3776-3787https://doi.org/10.1002/mp.13681
- Fast and insightful bi-objective optimization for prostate cancer treatment planning with high-dose-rate brachytherapy.Appl Soft Comput J. 2019; 84105681https://doi.org/10.1016/j.asoc.2019.105681
- A multi-protocol validation study of automated bi-objective planning for HDR prostate brachytherapy.WCB Abstr. 2021; : P0-0233
- The EU medical device regulation: Implications for artificial intelligence-based medical device software in medical physics.Phys Medica. 2021; 83: 1-8https://doi.org/10.1016/j.ejmp.2021.02.011
- Intelligent inverse treatment planning via deep reinforcement learning, a proof-of-principle study in high dose-rate brachytherapy for cervical cancer.Phys Med Biol. 2019; 64https://doi.org/10.1088/1361-6560/ab18bf
- Evaluating the impact of real-time multicriteria optimizers integrated with interactive plan navigation tools for HDR brachytherapy.Brachytherapy. 2020; 19: 607-617https://doi.org/10.1016/j.brachy.2020.06.016
Maree SC, Alderliesten T, Bosman PAN. Ensuring smoothly navigable approximation sets by Bezier curve parameterizations in evolutionary bi-objective optimization – applied to brachytherapy treatment planning for prostate cancer. 2020:1–23.
- OC-0275 Incorporating control of contiguous high-dose volumes in automated optimization for prostate BT.Radiother Oncol. 2022; 170: S232-S234https://doi.org/10.1016/s0167-8140(22)02533-6
- Bi-objective optimization of catheter positions for high-dose-rate prostate brachytherapy.Med Phys. 2020; 47: 6077-6086https://doi.org/10.1002/mp.14505
Article info
Publication history
Published online: January 10, 2023
Accepted:
November 28,
2022
Received in revised form:
October 28,
2022
Received:
July 8,
2022
Publication stage
In Press Corrected ProofFootnotes
Disclosures: Prof. Bel has involvement in several Elekta and Varian sponsored projects. Dr. Pieters has involvement in Elekta sponsored projects and is consultant for BD. Prof. Bosman and Dr. Alderliesten have research collaboration with Elekta. These companies had no involvement in study design, data collection and analysis, or writing of the manuscript. We disclose any and all potential conflicts of interest that could bias the results reported in the manuscript.
Identification
Copyright
© 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
